Veracyte (VCYT) Tops Q2 EPS by 33c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Vertiv shares fall on analyst downgrades and options bets
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- S&P 500 ends higher as traders shift from AI to healthcare
- Caterpillar names Derrick York to lead Resource Industries
- Intel shares drop on foundry risks, sector pressures
Veracyte, Inc (VCYT) PT Lowered to $28 at Morgan Stanley
August 8, 2025 2:49 PM EDTMorgan Stanley analyst Tejas Savant lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $28.00 (from $29.00) while maintaining a Underweight rating.
The analyst comments "Solid 2Q beat on continued Decipher/Afirma momentum leading to '25 guidance raise; total company guidance now initiated following Veracyte SAS... More



